Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct

Histopathology

Volumn 60, Issue 7, 2012, Pages 1052-1059

  Finkelstein, Alexander ^a   Levy, Gillian H ^a   Hui, Pei ^a   Prasad, Avinash ^b   Virk, Renu ^a   Chhieng, David C ^a   Carling, Tobias ^a   Roman, Sanziana A ^a   Sosa, Julie A ^a   Udelsman, Robert ^a   Theoharis, Constantine G ^a   Prasad, Manju L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

BRAF mutation; Molecular testing; Papillary; Thyroid; Thyroid carcinoma

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER MORPHOLOGY; CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; DNA POLYMORPHISM; EOSINOPHIL; FEMALE; FIBROSIS; GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PSAMMOMA BODY; STROMAL FIBROSIS; SUBCAPSULAR SCLEROSING MICROCARCINOMA; THYROID CARCINOMA; TUMOR CELL;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CARCINOMA, PAPILLARY; CHILD; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTANT PROTEINS; MUTATION, MISSENSE; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84861480417     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04149.x     Document Type: Article

References (27)

1. Cohen Y, Xing M, Mambo E et al. BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst. 2003; 95; 625-627.
2. Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003; 88; 5399-5404.
3. Trovisco V, Vieira de Castro I, Soares P et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 2004; 202; 247-251.
4. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417; 949-954.
5. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6; 313-319.
6. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 2005; 12; 245-262.
7. Namba H, Nakashima M, Hayashi T et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 2003; 88; 4393-4397.
8. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med. J. 2004; 45; 818-821.
9. Xing M, Westra WH, Tufano RP et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2005; 90; 6373-6379.
10. Jin L, Sebo TJ, Nakamura N et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn. Mol. Pathol. Am. J. Surg. Pathol. B 2006; 15; 136-143.
11. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110; 38-46.
12. Kebebew E, Weng J, Bauer J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 2007; 246; 466-470. discussion 470-471.
13. Groussin L, Fagin JA. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat. Clin. Pract. Endocrinol. Metab. 2006; 2; 180-181.
14. Lupi C, Giannini R, Ugolini C et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2007; 92; 4085-4090.
15. Frasca F, Nucera C, Pellegriti G et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr. Relat. Cancer 2008; 15; 191-205.
16. Vasko V, Hu S, Wu G et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J. Clin. Endocrinol. Metab. 2005; 90; 5265-5269.
17. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998; 83; 2638-2648.
18. Rivera M, Ricarte-Filho J, Tuttle RM et al. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid 2010; 20; 1085-1093.
19. DeLellis RA, Lloyd RV, Heitz PU, Eng C eds. World Health Organization classification of tumours. Lyon: IARC Press, 2004.
20. Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid Off. J. Am. Thyroid Assoc. 2008; 18; 1179-1181.
21. Baloch ZW, Cibas ES, Clark DP et al. The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. CytoJournal 2008; 5; 6.
22. Adeniran AJ, Theoharis C, Hui P et al. Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid 2011; 21; 717-723.
23. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III. American Joint Committee on Cancer: cancer staging manual, 7th edn. Chicago, IL: Springer, 2010.
24. Adeniran AJ, Zhu Z, Gandhi M et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 2006; 30; 216-222.
25. Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod. Pathol. 2007; 20; 779-787.
26. Mesa C Jr, Mirza M, Mitsutake N et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 2006; 66; 6521-6529.
27. Bhaijee F, Nikiforov YE. Molecular analysis of thyroid tumors. Endocr. Pathol. 2011; 22; 126-133.